2004
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors
Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemotherapy And Pharmacology 2004, 54: 308-314. PMID: 15184994, DOI: 10.1007/s00280-004-0816-z.Peer-Reviewed Original ResearchConceptsPharmacokinetics of carboplatinTNP-470Solid tumorsDoublet regimenAngiogenesis inhibitor TNP-470Hematological toxic effectsRegimen of paclitaxelCycles of therapyMedian survival durationCombination of paclitaxelPatient survival ratesRecent clinical trialsHead/neckCell lung carcinomaTNP-470 administrationToxic effectsAUC 5AUC 6Chemotherapy doubletsIntravenous paclitaxelPurposePreclinical studiesStable diseasePartial responseRandomized studySurvival duration
2002
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. PMID: 12422310, DOI: 10.1053/sonc.2002.35644.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activityIMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer
Herbst R, Hong W. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. DOI: 10.1016/s0093-7754(02)70087-0.Peer-Reviewed Original ResearchSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activity